Overview

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai JMT-Bio Inc.
Treatments:
Denosumab